| 32.55 0.42 (1.31%) | 07-08 12:37 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 39.71 | 1-year : | 46.39 |
| Resists | First : | 34 | Second : | 39.71 |
| Pivot price | 30.48 |
|||
| Supports | First : | 27.59 | Second : | 23.62 |
| MAs | MA(5) : | 31.32  |
MA(20) : | 29.48 |
| MA(100) : | 27.84 |
MA(250) : | 17.09 |
|
| MACD | MACD : | 0.4 |
Signal : | 0 |
| %K %D | K(14,3) : | 60.8 |
D(3) : | 60.8 |
| RSI | RSI(14): 55.3 |
|||
| 52-week | High : | 43.84 | Low : | 7.15 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ STRO ] has closed below upper band by 22.1%. Bollinger Bands are 35.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 33.4 - 33.53 | 33.53 - 33.67 |
| Low: | 29.4 - 29.53 | 29.53 - 29.66 |
| Close: | 31.91 - 32.14 | 32.14 - 32.39 |
Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and manufacturing of innovative therapeutic products. Its primary objective is to create protein-based treatments for challenging conditions like cancer and autoimmune disorders. The company achieves this through its proprietary XpressCF+ platform, a unique technology that integrates cell-free protein synthesis with precise, site-specific drug conjugation. Currently, Sutro's pipeline features two lead antibody-drug conjugate (ADC) candidates, both undergoing Phase 1 clinical evaluation. STRO-001 targets the CD74 protein, designed for individuals with multiple myeloma and non-Hodgkin lymphoma. The second candidate, STRO-002, is engineered to bind to folate receptor-alpha, intended for the treatment of ovarian and endometrial cancers. Strategic alliances are also a key part of its strategy, including collaborations and licensing agreements. A partnership with Merck aims to advance research programs involving cytokine derivatives for both oncological and autoimmune applications. Additionally, an agreement with Celgene Corporation focuses on identifying and developing bispecific antibodies and/or ADCs specifically within the immuno-oncology domain. Founded in 2003, the company initially operated under the name Fundamental Applied Biology, Inc. Its corporate headquarters are located in South San Francisco, California.
Wed, 08 Jul 2026
Enterprise value to EBITDA forward of Sutro Biopharma, Inc. – NASDAQ:STRO - TradingView
Sat, 04 Jul 2026
Sutro Biopharma (STRO) price target increased by 13.85% to 37.74 - MSN
Mon, 29 Jun 2026
Sutro Biopharma, Inc.(NasdaqGM: STRO) added to Russell 2000 Index - marketscreener.com
Mon, 29 Jun 2026
Sutro Biopharma, Inc.(NasdaqGM: STRO) added to Russell 3000E Index - marketscreener.com
Sun, 28 Jun 2026
Sutro Biopharma, Inc.(NasdaqGM: STRO) added to Russell 3000 Growth Benchmark - marketscreener.com
Tue, 09 Jun 2026
Sutro Biopharma (STRO) director receives 10,000 stock options at $26.09 - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 17 (M) |
| Shares Float | 10 (M) |
| Held by Insiders | 2.2 (%) |
| Held by Institutions | 86.8 (%) |
| Shares Short | 922 (K) |
| Shares Short P.Month | 1,190 (K) |
| EPS | -16.36 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -4.04 |
| Profit Margin | -154.3 % |
| Operating Margin | -204 % |
| Return on Assets (ttm) | -19.4 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | -16.5 % |
| Gross Profit (p.s.) | -3.95 |
| Sales Per Share | 6.01 |
| EBITDA (p.s.) | -4.86 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -152 (M) |
| Levered Free Cash Flow | -106 (M) |
| PE Ratio | -1.97 |
| PEG Ratio | 0 |
| Price to Book value | -7.96 |
| Price to Sales | 5.34 |
| Price to Cash Flow | -3.52 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|